WO2016172042A1 - Polymer systems and their applications in diagnostics and drug delivery - Google Patents

Polymer systems and their applications in diagnostics and drug delivery Download PDF

Info

Publication number
WO2016172042A1
WO2016172042A1 PCT/US2016/028104 US2016028104W WO2016172042A1 WO 2016172042 A1 WO2016172042 A1 WO 2016172042A1 US 2016028104 W US2016028104 W US 2016028104W WO 2016172042 A1 WO2016172042 A1 WO 2016172042A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
composition
composition according
mmol
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/028104
Other languages
French (fr)
Inventor
Naga Venkata Ravi Kumar MAJETI
Prabhjot SAINI
Raghu GANUGULA
Harshad SHETE
Meenakshi ARORA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Priority to US15/567,370 priority Critical patent/US10780175B2/en
Publication of WO2016172042A1 publication Critical patent/WO2016172042A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C08G63/6852—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C08G63/912—Polymers modified by chemical after-treatment derived from hydroxycarboxylic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2230/00—Compositions for preparing biodegradable polymers

Definitions

  • the present invention provides a biodegradable polymer system and methods for preparing pharmaceutically effective polymer nanosystems for delivery and/or targeting of drugs or drug like compounds.
  • Biodegradable polymers have been used as surgical sutures, wound dressings, and as drug delivery systems. Among them, polylactide (PLA), polyglycolide (PGA) and their copolymers (PLGA) have attracted the most attention.
  • PLA polylactide
  • PGA polyglycolide
  • PLGA copolymers
  • copolymer-based drug carriers do not exhibit efficient targeted delivery of drug compositions.
  • the present invention provides biodegradable polymer system compositions and methods for preparing a pharmaceutically effective polymer nanosystems for delivery and/or targeting of drugs or drug like compounds.
  • the present invention also provides a method for preparing the biodegradable drug delivery composition and a method for effectively administering such a composition to whole body systems eg animals, humans.
  • the drug delivery composition of the present invention can be administered without an aqueous vehicle, or can be administered after being reconstituted in an aqueous vehicle to afford a stable suspension.
  • the administration can be done by peroral means.
  • the drug compositions may be administered via the nose or skin and can be injectable.
  • the present invention describes a novel biodegradable polymer system compositions and methods for preparing pharmaceutically effective polymer nanosystems for delivery of drugs or drug like compounds precisely where it is needed in the body with minimal non-target effects.
  • Embodiments of the invention are directed to creating biodegradable repeating units with a specific biological function that can form polymer nanosystem with defined size and function e.g., improve intestinal uptake of the polymer nanosystem containing bioactive(s) and/or direct them to a specific site of action to deliver the pay load e.g., tumor epithelium or inflamed endothelium or a specific organ of interest.
  • polymer systems/polymer nanosystems go beyond the current available systems in that they allow optimization of ligand-receptor stoichiometry which is the key to achieve ideal receptor mediated delivery of the bioactives.
  • Most nanomedicines that are currently under development are single bioactive based.
  • the polymer nanosystems allow a combination of bioactives, where such systems are advantageous in the treatment of several diseases e.g., diabetes, cancer, cardiovascular.
  • These systems offers flexibility of converting the molecules that are administered by injections to orally/peroral viable medicines, and can avoid refrigerated storage.
  • These polymer systems/polymer nanosystems can serve as a platform technology for a variety of bioactives and diseases in that, the bioactive(s) encapsulated and the surface ligands specific to receptor can be varied in a manner that suits a disease of interest.
  • These polymer nanosystems can be designed such a way by varying the molecular weight of the building blocks so that the encapsulated bioactive(s) are released over several days.
  • These polymer nanosystems can be appropriately tailored making them route independent, in that they can be administered via mouth, nose, skin or can be injectable.
  • These polymer nanosystems can be ideal for existing bioactives to improve their performance as well as for new indications.
  • the composition of the present invention comprises: 1) one or more biodegradable block copolymer drug carriers comprising A-B, A-B-A or B-A-B block, with chain linkers imparting periodic pendent carboxyl or amine functional groups throughout the polymer backbone, wherein the A block is a biodegradable polyester and the B block is polyethylene glycol (PEG) with the weight percentage of the A block is between 1% to 99%; and chain linker is an aromatic or aliphatic tetracarboxylic dianhydride and 2) a polyethylene glycol (PEG), a PEG derivative, or a mixtures of PEG and a PEG derivative.
  • biodegradable polymers examples include ABA- or BAB- type triblock copolymers, or AB-type diblock copolymers based on biodegradable polyester A-blocks and hydrophilic B polymer block(s) consisting of polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • the biodegradable polyesters are synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, s-caprolactone, l,4-dioxan-2-one, s-hydroxy hexanoic acid, ⁇ -butyrolactone, ⁇ - hydroxy butyric acid, ⁇ -valerolactone, ⁇ -hydroxy valeric acid, hydroxybutyric acids, malic acid, and copolymers thereof.
  • Polyethylene glycol (PEG) is also sometimes referred to as poly(ethylene oxide) (PEO) or poly(oxyethylene) and the terms can be used interchangeably for the purposes of this invention.
  • the biodegradable block copolymer drug carriers suitable for the present invention can form homogeneous suspensions in an aqueous or any other suitable vehicle as desired.
  • Homogeneous suspensions of the drug delivery compositions include all flowing forms of the compositions of the present invention, with or without water, drug(s), and any additives or excipients as necessary to prepare formulations that are pharmaceutically and therapeutically useful.
  • the drug may be present as either a true solution or in a colloidal state such as emulsion or a suspension. All forms can act to facilitate administration of the drug and enhance the therapeutic effect.
  • Such therapeutic effects may be optimized by controlling the copolymer molecular weights, compositions, and the relative ratios of the hydrophilic and hydrophobic blocks, ratios of drug to copolymer, ratios of copolymer to PEG and/or PEG derivatives, concentration of the conjugated ligands to pendent carboxyl or amine functional groups, the particle size and both drug and copolymer concentrations in the final administered dosage form. Additional advantages of this invention will become apparent from the following detailed description of the various embodiments.
  • FIG. 1A shows the decrease in molecular weight of hP2-400 over a period of 96 hours in PBS at 37 °C;
  • FIG. IB shows the degradation profile of hP2-400 over a period of 96 hours in PBS at 37 °C;
  • FIG. 1C shows the decrease in molecular weight of hP2-1000H over a period of 96 hours in PBS at 37 °C;
  • FIG. 1 D shows the degradation profile of hP2- 1000H over a period of
  • FIG. IE shows the decrease in molecular weight of hP2-2000H over a period of 96 hours in PBS at 37 °C;
  • FIG. IF shows the degradation profile of hP2-2000H over a period of 96 hours in PBS at 37 °C;
  • FIG. 2 A shows the mean fluorescent intensity of fluorescent P2Ns of hP2-400 in RBCs
  • FIG. 2B shows the mean fluorescent intensity of fluorescent P2Ns of hP2-400 in plasma.
  • Biodegradable means that the block copolymer or oligomer can chemically break down or degrade within the body to form nontoxic components. The rate of degradation can be the same or different from the rate of drug release.
  • Drug shall mean any organic or inorganic compound or substance having biological or pharmacological activity that can be adapted or used for a therapeutic purpose.
  • Peptide “Pypeptide,” “oligopeptide” and “protein” shall be used interchangeably when referring to peptide or protein drugs and shall not be limited as to any particular molecular weight, peptide sequence or length, field of bioactivity or therapeutic use unless specifically stated.
  • PLA shall mean a polymer derived from the poly-condensation of lactic acid or by the ring opening polymerization of lactide.
  • Biodegradable polyester refers to any polymer preferably synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L- lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ⁇ -caprolactone, l,4-dioxan-2- one, ⁇ -hydroxy hexanoic acid, ⁇ -butyrolactone, ⁇ -hydroxy butyric acid, ⁇ -valerolactone, ⁇ - hydroxy valeric acid, hydroxybutyric acid, malic acid, ethyleneglycol and mixtures thereof.
  • the biodegradable polymer system comprises ABA-type or BAB -type triblock copolymers, AB-type diblock copolymers or mixtures thereof, where the A-blocks are relatively hydrophobic and comprises a biodegradable polyester, and the B-blocks are relatively hydrophilic and comprises polyethylene glycol (PEG).
  • A-blocks are relatively hydrophobic and comprises a biodegradable polyester
  • B-blocks are relatively hydrophilic and comprises polyethylene glycol (PEG).
  • the biodegradable polymer system comprises multiblock ABA- or BAB-type copolymers of lactic acid and ethylene glycol with periodically spaced side chain carboxyl groups. Multiple pendent carboxyl groups are imparted into the PLA-PEG backbone via the incorporation of an aromatic or aliphatic tetracarboxylic anhydride moiety in the chain extension step.
  • the tetracarboxylic dianhydrides that are used are pyromelltic dianhydride and cyclohexane tetracarboxylic dianhydride.
  • an embodiment of the present invention is directed to a variation of polymer system that is synthesized with a diamine linker conjugated to the carboxyl groups, such that one of the amine moieties of the linker is covalently bonded to the carboxyl of the polymer while the other remains free for conjugating ligands.
  • the two variations of the polymer, with free carboxyl and amine unit provides the flexibility to attach the ligands with either a free hydroxyl amine or carboxyl functionality respectively, without the need of any further alteration of either the polymer or ligand.
  • Polymers thus obtained can be used to form polymer nanosystem by appropriate methods.
  • the X-ray photoelectron spectroscopy (XPS) analysis performed on the polymer nanosystem shows that the ligands attached to the polymer system are displayed on the surface of the polymer nanosystem, which is imperative for their availability for binding to the respective receptors on the cells.
  • XPS X-ray photoelectron spectroscopy
  • the PEG, PEG derivatives or mixtures thereof used in the present invention dissolves or uniformly mixes with the biodegradable block copolymer and so reduces the viscosity and increases the fluidity of the composition.
  • the compositions of the present invention are flowable liquids or can be easily formulated with an aqueous vehicle to afford a homogeneous uniform colloidal system.
  • the composition can be easily administered as is or reconstituted with an aqueous or appropriate vehicle.
  • the block copolymer drug carrier may or may not form a drug depot. Therefore, the liquid PEG, PEG derivative or mixtures thereof of the present invention should be a material that does not cause loss of activity of the physiologically active substance.
  • Drugs that may be incorporated with the drug delivery compositions of the present invention can be any bioactive agent, but particular advantage is achieved with bioactive agents having limited solubility or dispersibility in an aqueous or hydrophilic environment, or any bioactive agent that requires enhanced solubility or permeability.
  • the choice of ligand conjugated to the polymer system will play an important role in the absorption and targetability of the polymer nanosystem and encapsulated drugs, thus enhancing their site/target specificity.
  • the present invention thus provides compositions comprising biodegradable block copolymer drug carriers and PEG, PEG derivatives or mixtures thereof that are powders or can be rapidly reconstituted in an aqueous vehicle to afford useful forms that are uniform colloidal systems.
  • the drug solution formed with the drug delivery compositions of the present invention has desirable physical stability, therapeutic efficacy, and toxicology.
  • the PEG, PEG derivatives or mixtures thereof of the present invention can be used for water soluble or water insoluble block copolymeric drug carriers, particularly for biodegradable di- or triblock copolymers that have reverse gelation properties and/or polymers that can enhance the solubility of drugs, especially hydrophobic drugs.
  • This example describes the synthesis of PLA-PEG400 block pre- polymer from 1-lactide and 7% (w/w) PEG-400.
  • This example describes the chain extension of the pre-polymer from example 1 with the incorporation of an aromatic linker to impart multifunctionality.
  • a 250 ml three necked round-bottomed flask fitted with a reflux condenser, magnetic stirrer, heat-on-block and under a gentle purge of nitrogen was charged with PLA-PEG400 (7 g; 0.6364 mmol), Pyromellitic dianhydride (166.56mg; 0.7636 mmol), Triethylamine (128.81 mg; 177.42 ⁇ ; 1.2728 mol), Stannous Octotate (7 mg; 5.6 ⁇ ; 0.1 w/w) and Toluene (40 ml).
  • reaction mixture was heated to a temperature of 115°C while stirring to allow the solvent to reflux.
  • the reaction was carried out under these conditions for 24 h, after which reaction mixture was cooled and solvent was evaporated under reduced pressure.
  • the residue dissolved in 10 ml methylene chloride and precipitated in 500 ml cold diethyl ether under vigorous stirring.
  • the white polymer was collected by filtration under suction and dried under vacuum to a constant dry weight (6.2 g).
  • This example describes the chain extension of the pre-polymer from example 1 with the incorporation of an aliphatic linker to impart multifunctionality.
  • reaction was carried out under these conditions for 24 h, after which reaction mixture was cooled and solvent was evaporated under reduced pressure. The residue dissolved in 10 ml methylene chloride and precipitated in 400 ml cold diethyl ether under vigorous stirring. The white polymer was collected by filtration under suction and dried under vacuum to a constant dry weight (6.1 g).
  • Example 4 [00039] This examples describes the synthetic process of the aminated version of hP2-400 (hP2-400-EDA) described in example 3 using EDA.
  • the dried polymer was dissolved in 2.2 ml of 10: 1 mixture of CH2C12:TFA and stirred at room temperature for 1 h under nitrogen atmosphere. The solvent was then stripped off on a rotary evaporator and product washed with water to get a white polymer.
  • the hP2-400-EDA polymer was dried under vacuum to a constant dry weight (195 mg).
  • Example 11 This example describes the conjugation of 1-Lysine to pP2-400 described in example 2.
  • Example 13 [00057] This example describes the conjugation of Arginine to pP2-400 described in example 2.
  • This example describes the conjugation of Paclitaxel to pP2-400 described in example 2.
  • This example describes the conjugation of Cisplatin to hP2-400 described in example 2.
  • a 50 ml three necked round bottom flask equipped with a magnetic stirrer and under a gentle purge of nitrogen was charged with pP2-400 (100 mg; 0.1 mmol; 8 COOH/mol), EDC (19.71 mg; 0.1 mmol) and DMF (1 ml) and stirred at ambient temperature for 30 min.
  • Cisplatin (30 mg; 0.1 mmol) predissolved in DMF (1 ml) and DIEA (12.92 mg; 17.42 ⁇ ; 0.1 mmol) were subsequently added to the reaction flask and the reaction was carried out in the dark under nitrogen atmosphere and room temperature for 24 h.
  • a yellow conjugated polymer was obtained by precipitation in water. The polymer was further washed twice with water and dried under vacuum to a constant dry weight (84.3 mg).
  • This example describes the conjugation of Withaferin A to pP2-2000H (A variation of pP2-400 described in example 2 with 2000 g/mol PEG chains and higher lactide concentration per chain of final polymer).
  • P2s can be functionalized with diagnostic agents e.g. MRI and ultrasound contrast agents, Near-IR fluorescent agents etc. by coupling them to the carboxyl or amine functionality of the P2s via ester or amide bonds based on the available functional unit of the agent. Both the processes involve activation of carboxyl on either the polymer or the diagnostic moiety by EDC followed by either amination in the presence of DIEA or esterification in the presence of DMAP. Alternatively, Fischer esterification can be employed to conjugate a moiety with hydroxyl functionality to the carboxylated P2, if the said moiety can withstand higher temperatures and strong acid catalyst.
  • diagnostic agents e.g. MRI and ultrasound contrast agents, Near-IR fluorescent agents etc.
  • FIG. 1C shows the decrease in molecular weight of hP2-1000H and Fig. ID shows the degradation profile of hP2-1000H over a period of 96 hours.
  • Fig. IE shows the decrease in molecular weight of hP2-2000H and Fig. IF shows the degradation profile of hP2-2000H over a period of 96 hours.
  • This example describes the general preparation of NS of P2s.
  • the NS were collected by centrifugation at 15000-20000xg at 4°C for 30 minutes.
  • the pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried.
  • the emulsification process can be modified based on the physico-chemistry of different drugs to be encapsulated to maximize entrapment efficiency.
  • NS To prepare NS, 25 mg of hP2-400 or conjugated hP2-400 (with additional plain polymer equal to cumulative ligand weight) were mixed with 1 mg hP2-400-fluorescein and the mixture was solubilized in 1.25 ml (2% w/v) in a 1 :4 mixture of CH2C12 and ethyl acetate. The organic phase was emulsified in a 2.5 ml (1% or 0.5 %w/v) solution of DMAB. The emulsion was stirred at 1500 rpm for 5 min followed by homogenization at 15000 rpm for 7 min. The final emulation was diluted with 10 ml water and stirred at 100 rpm for 3 h. The NS were collected by centrifugation at 15000-20000xg at 4°C for 30 minutes. The pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried.
  • Example 23 [00077] This example describes the encapsulation of Paclitaxel in NS of P2s.
  • paclitaxel loaded NS 50 mg P2s and paclitaxel (5, 10, 15 or 20% w/w based on loading amount) were solubilized in 5 ml mixture of CH2C12 and ethyl acetate (based on their solubility; tablel) and emulsified in a 5 ml (1% w/v) solution of DMAB.
  • the emulsion was stirred at 1500 rpm for 5 min followed by homogenization at 15000 rpm for 5 min.
  • the final emulation was diluted with 20 ml water and stirred at 1000 rpm for 3 h.
  • the NS were collected by centrifugation at 15000xg at 4°C for 30 minutes.
  • the pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried.
  • Example 24 This example describes the encapsulation of Insulin in NS of P2s.
  • Insulin loaded P2s-NS were prepared using a double emulsion technique. 50 mg P2s were dissolved in 3 ml mixture of CH2C12 and ethyl acetate (based on their solubility; tablel). Insulin was separately dissolved in 0.5 ml 1.5% (w/v) solution of PVA in 0.01M HC1 in an amount equal to 5, 10 or 15% (w/w) of the polymer content based on intended loading. The aqueous phase containing insulin was emulsified in the organic phase containing polymer and stirred at 1500 rpm for 3 min.
  • this primary emulsion was then added to 10.5 ml 1.5% (w.v) PVA solution in water to form a secondary emulsion which was further stirred for 3 min at 1500 rpm.
  • the emulsion was homogenized at 15000 rpm for 7 min followed by dilution in 20 ml water.
  • the final suspension was stirred for 3 h at 1000 rpm to allow the organic solvent to diffuse out and evaporate.
  • the NS were collected by centrifugation at 15000xg at 4°C for 30 minutes.
  • the pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried.
  • cyclosporine A loaded NS 50 mg P2s and cyclosporine A (5, 10 or 15% w/w based on loading amount) were solubilized in 2.5 ml mixture of CH2C12 and Ethyl acetate (based on their solubility; tablel) and emulsified in a 5 ml (0.1% w/v) solution of DMAB. The emulsion was stirred at 1500 rpm for 1 min followed by probe sonication at 20% amplitude for 30 s. The final emulation was diluted with 20 ml water and stirred at 1000 rpm for 3 h. The NS were collected by centrifugation at 15000xg at 4°C for 30 minutes. The pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried.
  • Example 26 [00083] This example describes the uptake of fluorescent P2Ns of hP2-400 described in example 22 in Caco-2 cells monolayers.
  • Freeze-dried fluorescent P2NS and PLGA NS (plain or conjugated to GA, Gal or RGD) were suspended in dH20 at a concentration of 50 and 250 ⁇ g/ml respectively.
  • Caco-2 cells were incubated with the 200 ⁇ of F-NS suspension for 5 min at 37 °C/5% C02, followed by addition serum free medium and further incubation for lh at 37 °C/5% C02.
  • the cells were washed three times with phosphate buffered saline (PBS, pH 7.4) and further processed for fluorescent microscopy and FACS for uptake.
  • PBS phosphate buffered saline
  • This example describes the evaluation of non -competitive binding of fluorescent P2Ns-GA of hP2-400 described in example 22 to transferrin receptor (TfR) in Caco-2 cells monolayers.
  • TfR transferrin receptor
  • TfR primary antibody by incubating for 30 min at 37°C in CO 2 incubator. After three consecutive washings with PBS, P2Ns-GA were added and incubated for further 1 h. These were then washed with PBS 3 times and trypsinized and subjected to FACS analysis.
  • Example 28 [00087] This example describes the uptake of fluorescent P2Ns of hP2-400 described in example 22 in ex vivo intestinal tissue.
  • This example describes the evaluation of non -competitive binding of fluorescent P2Ns-GA of hP2-400 described in example 22 to transferrin receptor (TfR) in ex vivo small intestine tissue sections.
  • TfR on 4 ⁇ cryosections of previously excised small intestine were blocked using human/mouse specific TfR primary antibody by incubating for 30 min at 37°C in CO 2 incubator. After three consecutive washings with PBS, P2Ns-GA were added and incubated for further 1 h. These were then washed with PBS 3 times and processed for microscopic evaluation.
  • This example describes the kinetics of fluorescent P2Ns of hP2-400 described in example 22 in vivo in Sprague Dawley rats.
  • Male Sprague Dawley rats 300-320 g were dosed perorally with fluorescent plain and conjugated P2Ns (16 mg/rat). Blood was collected via heart puncture at terminal sacrifice at 2, 12 and 24 h. Plasma and RBCs were processed for fluorescence quantification. The plasma kinetics shows ligand specific variable absorption, where those with no ligands were absorbed over extended periods of times suggesting they are lodged in the intestine.
  • Fig. 2A shows the mean fluorescent intensity of fluorescent P2Ns of hP2-400 in RBCs.
  • Fig. 2B shows the mean fluorescent intensity of fluorescent P2Ns of hP2-400 in plasma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a biodegradable "precision polymer system" (poly system) and methods for preparing pharmaceutically effective "precision polymer nanosystems" (polymer nanosystem) for delivery and/or targeting of drugs or drug like compounds.

Description

POLYMER SYSTEMS AND THEIR APPLICATIONS IN DIAGNOSTICS AND DRUG
DELIVERY
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S.
Provisional Patent Application No. 62/149,563, filed April 18, 2015, which is incorporated herein by reference in its entirety as if fully set forth herein.
FIELD OF THE INVENTION [0002] The present invention provides a biodegradable polymer system and methods for preparing pharmaceutically effective polymer nanosystems for delivery and/or targeting of drugs or drug like compounds.
BACKGROUND OF THE INVENTION
[0003] Biodegradable polymers have been used as surgical sutures, wound dressings, and as drug delivery systems. Among them, polylactide (PLA), polyglycolide (PGA) and their copolymers (PLGA) have attracted the most attention.
[0004] Currently there are few synthetic or natural polymeric materials that can be used for the controlled and targeted delivery of drugs, including peptide and protein drugs, because of strict regulatory compliance requirements such as biocompatibility, low toxicity, having a clearly defined degradation pathway, and safety of the polymers and degradation products. The most widely investigated and advanced biodegradable polymers in regard to available toxicological and clinical data are the aliphatic poly(a-hydroxy acids), such as poly(D-, L-, or D, L-lactic acid) (PLA) with varying stereochemistry (L, D or DL), poly(glycolic acid) (PGA) and their copolymers (PLGA). These polymers are commercially available and are presently used as bioresorbable sutures and in biodegradable microsphere drug delivery systems.
[0005] Even though there has been some success, the success at large is limited by the inability of the commercially available polymers as platforms for wide variety of drugs with distinct physicochemical attributes eg solubility, molecular weight, permeability.
Additionally, currently known copolymer-based drug carriers do not exhibit efficient targeted delivery of drug compositions. [0006] Thus, it would be beneficial to have a polymer system that have the ability to optimize ligand-receptor stoichiometry facilitating a receptor-specific targeted delivery combined with tunable release property and further lends itself to facilitate the delivery of compounds with distinct physicochemical attributes.
SUMMARY OF THE INVENTION
[0007] The present invention provides biodegradable polymer system compositions and methods for preparing a pharmaceutically effective polymer nanosystems for delivery and/or targeting of drugs or drug like compounds.
[0008] The present invention also provides a method for preparing the biodegradable drug delivery composition and a method for effectively administering such a composition to whole body systems eg animals, humans. The drug delivery composition of the present invention can be administered without an aqueous vehicle, or can be administered after being reconstituted in an aqueous vehicle to afford a stable suspension. The administration can be done by peroral means. Additionally, the drug compositions may be administered via the nose or skin and can be injectable.
[0009] The present invention describes a novel biodegradable polymer system compositions and methods for preparing pharmaceutically effective polymer nanosystems for delivery of drugs or drug like compounds precisely where it is needed in the body with minimal non-target effects. Embodiments of the invention are directed to creating biodegradable repeating units with a specific biological function that can form polymer nanosystem with defined size and function e.g., improve intestinal uptake of the polymer nanosystem containing bioactive(s) and/or direct them to a specific site of action to deliver the pay load e.g., tumor epithelium or inflamed endothelium or a specific organ of interest. These polymer systems/polymer nanosystems go beyond the current available systems in that they allow optimization of ligand-receptor stoichiometry which is the key to achieve ideal receptor mediated delivery of the bioactives. Most nanomedicines that are currently under development are single bioactive based. However, the polymer nanosystems allow a combination of bioactives, where such systems are advantageous in the treatment of several diseases e.g., diabetes, cancer, cardiovascular. These systems offers flexibility of converting the molecules that are administered by injections to orally/peroral viable medicines, and can avoid refrigerated storage. These polymer systems/polymer nanosystems can serve as a platform technology for a variety of bioactives and diseases in that, the bioactive(s) encapsulated and the surface ligands specific to receptor can be varied in a manner that suits a disease of interest. These polymer nanosystems can be designed such a way by varying the molecular weight of the building blocks so that the encapsulated bioactive(s) are released over several days. These polymer nanosystems can be appropriately tailored making them route independent, in that they can be administered via mouth, nose, skin or can be injectable. These polymer nanosystems can be ideal for existing bioactives to improve their performance as well as for new indications.
[00010] The composition of the present invention comprises: 1) one or more biodegradable block copolymer drug carriers comprising A-B, A-B-A or B-A-B block, with chain linkers imparting periodic pendent carboxyl or amine functional groups throughout the polymer backbone, wherein the A block is a biodegradable polyester and the B block is polyethylene glycol (PEG) with the weight percentage of the A block is between 1% to 99%; and chain linker is an aromatic or aliphatic tetracarboxylic dianhydride and 2) a polyethylene glycol (PEG), a PEG derivative, or a mixtures of PEG and a PEG derivative.
[00011] Examples of suitable biodegradable polymers includes ABA- or BAB- type triblock copolymers, or AB-type diblock copolymers based on biodegradable polyester A-blocks and hydrophilic B polymer block(s) consisting of polyethylene glycol (PEG). The biodegradable polyesters are synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, s-caprolactone, l,4-dioxan-2-one, s-hydroxy hexanoic acid, γ-butyrolactone, γ- hydroxy butyric acid, δ-valerolactone, δ-hydroxy valeric acid, hydroxybutyric acids, malic acid, and copolymers thereof. Polyethylene glycol (PEG) is also sometimes referred to as poly(ethylene oxide) (PEO) or poly(oxyethylene) and the terms can be used interchangeably for the purposes of this invention.
[00012] The biodegradable block copolymer drug carriers suitable for the present invention can form homogeneous suspensions in an aqueous or any other suitable vehicle as desired. Homogeneous suspensions of the drug delivery compositions include all flowing forms of the compositions of the present invention, with or without water, drug(s), and any additives or excipients as necessary to prepare formulations that are pharmaceutically and therapeutically useful. The drug may be present as either a true solution or in a colloidal state such as emulsion or a suspension. All forms can act to facilitate administration of the drug and enhance the therapeutic effect. Such therapeutic effects may be optimized by controlling the copolymer molecular weights, compositions, and the relative ratios of the hydrophilic and hydrophobic blocks, ratios of drug to copolymer, ratios of copolymer to PEG and/or PEG derivatives, concentration of the conjugated ligands to pendent carboxyl or amine functional groups, the particle size and both drug and copolymer concentrations in the final administered dosage form. Additional advantages of this invention will become apparent from the following detailed description of the various embodiments.
BRIEF DESCRIPTION OF THE DRAWINGS
[00013] FIG. 1A shows the decrease in molecular weight of hP2-400 over a period of 96 hours in PBS at 37 °C;
[00014] FIG. IB shows the degradation profile of hP2-400 over a period of 96 hours in PBS at 37 °C;
[00015] FIG. 1C shows the decrease in molecular weight of hP2-1000H over a period of 96 hours in PBS at 37 °C; [00016] FIG. 1 D shows the degradation profile of hP2- 1000H over a period of
96 hours in PBS at 37 °C;
[00017] FIG. IE shows the decrease in molecular weight of hP2-2000H over a period of 96 hours in PBS at 37 °C;
[00018] FIG. IF shows the degradation profile of hP2-2000H over a period of 96 hours in PBS at 37 °C;
[00019] FIG. 2 A shows the mean fluorescent intensity of fluorescent P2Ns of hP2-400 in RBCs; and
[00020] FIG. 2B shows the mean fluorescent intensity of fluorescent P2Ns of hP2-400 in plasma. DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
[00021] "Biodegradable" means that the block copolymer or oligomer can chemically break down or degrade within the body to form nontoxic components. The rate of degradation can be the same or different from the rate of drug release. [00022] "Drug" shall mean any organic or inorganic compound or substance having biological or pharmacological activity that can be adapted or used for a therapeutic purpose.
[00023] "Peptide," "polypeptide," "oligopeptide" and "protein" shall be used interchangeably when referring to peptide or protein drugs and shall not be limited as to any particular molecular weight, peptide sequence or length, field of bioactivity or therapeutic use unless specifically stated.
[00024] "PLA" shall mean a polymer derived from the poly-condensation of lactic acid or by the ring opening polymerization of lactide.
[00025] "Biodegradable polyester refers to any polymer preferably synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L- lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ε-caprolactone, l,4-dioxan-2- one, ε-hydroxy hexanoic acid, γ-butyrolactone, γ-hydroxy butyric acid, δ-valerolactone, δ- hydroxy valeric acid, hydroxybutyric acid, malic acid, ethyleneglycol and mixtures thereof.
[00026] In one embodiment, the biodegradable polymer system comprises ABA-type or BAB -type triblock copolymers, AB-type diblock copolymers or mixtures thereof, where the A-blocks are relatively hydrophobic and comprises a biodegradable polyester, and the B-blocks are relatively hydrophilic and comprises polyethylene glycol (PEG).
[00027] In another embodiment, the biodegradable polymer system comprises multiblock ABA- or BAB-type copolymers of lactic acid and ethylene glycol with periodically spaced side chain carboxyl groups. Multiple pendent carboxyl groups are imparted into the PLA-PEG backbone via the incorporation of an aromatic or aliphatic tetracarboxylic anhydride moiety in the chain extension step. In certain embodiments of the invention, the tetracarboxylic dianhydrides that are used are pyromelltic dianhydride and cyclohexane tetracarboxylic dianhydride.
[00028] In addition, an embodiment of the present invention is directed to a variation of polymer system that is synthesized with a diamine linker conjugated to the carboxyl groups, such that one of the amine moieties of the linker is covalently bonded to the carboxyl of the polymer while the other remains free for conjugating ligands. The two variations of the polymer, with free carboxyl and amine unit, provides the flexibility to attach the ligands with either a free hydroxyl amine or carboxyl functionality respectively, without the need of any further alteration of either the polymer or ligand. [00029] As proof of concept some embodiments of the present invention, have been synthesized with PLA and PEG blocks and aromatic or aliphatic linkers imparting multiple pendent carboxyl groups in the polymer backbone. The polymers are characterized using nuclear magnetic resonance (NMR) and gel permeation chromatography (GPC) to verify their chemistry and evaluate their molecular weight. As described above, carboxyl groups for certain embodiments of invention are capped with diamine moieties. Both the variations of polymer nanosystem, with pendent carboxyl and amine groups are further conjugated to ligands with free reactive hydroxyl, amine or carboxyl functionalities.
Polymers thus obtained can be used to form polymer nanosystem by appropriate methods. The X-ray photoelectron spectroscopy (XPS) analysis performed on the polymer nanosystem shows that the ligands attached to the polymer system are displayed on the surface of the polymer nanosystem, which is imperative for their availability for binding to the respective receptors on the cells.
[00030] The PEG, PEG derivatives or mixtures thereof used in the present invention dissolves or uniformly mixes with the biodegradable block copolymer and so reduces the viscosity and increases the fluidity of the composition. The compositions of the present invention are flowable liquids or can be easily formulated with an aqueous vehicle to afford a homogeneous uniform colloidal system. The composition can be easily administered as is or reconstituted with an aqueous or appropriate vehicle. After the administration, the block copolymer drug carrier may or may not form a drug depot. Therefore, the liquid PEG, PEG derivative or mixtures thereof of the present invention should be a material that does not cause loss of activity of the physiologically active substance. [00031] Drugs that may be incorporated with the drug delivery compositions of the present invention can be any bioactive agent, but particular advantage is achieved with bioactive agents having limited solubility or dispersibility in an aqueous or hydrophilic environment, or any bioactive agent that requires enhanced solubility or permeability. In addition, the choice of ligand conjugated to the polymer system will play an important role in the absorption and targetability of the polymer nanosystem and encapsulated drugs, thus enhancing their site/target specificity.
[00032] The present invention thus provides compositions comprising biodegradable block copolymer drug carriers and PEG, PEG derivatives or mixtures thereof that are powders or can be rapidly reconstituted in an aqueous vehicle to afford useful forms that are uniform colloidal systems. The drug solution formed with the drug delivery compositions of the present invention has desirable physical stability, therapeutic efficacy, and toxicology. The PEG, PEG derivatives or mixtures thereof of the present invention can be used for water soluble or water insoluble block copolymeric drug carriers, particularly for biodegradable di- or triblock copolymers that have reverse gelation properties and/or polymers that can enhance the solubility of drugs, especially hydrophobic drugs.
WORKING EXAMPLES
ABBREVIATIONS
CH2C12 Methylene Chloride DIEA N,N-diisoethylpropylamine
DMAB Didodecyldimethylammonium bromide
DMAP 4-Dimethylaminopyridine
DMF N,N-dimethylformamide
EDA Ethylenediamine EDC l-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
GA Gambogic acid
GaL Galactose RGD Arginylglycylaspartic acid
PVA Polyvinyl alcohol)
TFA Trifluoroacetic acid
TfR Transferrin receptor TPGS D-a-Tocopheryl polyethylene glycol 1000 succinate
NS Nanosystems
P2s Precision polymers
PLGA Polylactide-co-glycolide
P2Ns Ligand functional precision polymer nanosystems Example 1
[00033] This example describes the synthesis of PLA-PEG400 block pre- polymer from 1-lactide and 7% (w/w) PEG-400.
[00034] A 250 ml three necked round-bottomed flask fitted with a reflux condenser, magnetic stirrer, heat-on-block and under a gentle purge of nitrogen, was charged with 1-Lactide (18.0 g; 0.125 mol), PEG400 (3.52 g; 2.65 ml; 0.0088 mol), Stannous Octoate (21.52 mg; 17.20 μΐ; 0.1% w/w), Toluene (50 ml). The reaction mixture was heated to a temperature of 115°C while stirring to allow the solvent to reflux. The reaction was carried out under these conditions for 24 h, after which reaction mixture was cooled and solvent was evaporated under reduced pressure. The residue left upon evaporation of solvent was dissolved in 12 ml methylene chloride and precipitated in 400 ml cold diethyl ether under vigorous stirring. The white polymer was obtained by filtration under suction and dried under vacuum to a constant dry weight (16 mg).
Example 2
[00035] This example describes the chain extension of the pre-polymer from example 1 with the incorporation of an aromatic linker to impart multifunctionality. [00036] A 250 ml three necked round-bottomed flask fitted with a reflux condenser, magnetic stirrer, heat-on-block and under a gentle purge of nitrogen was charged with PLA-PEG400 (7 g; 0.6364 mmol), Pyromellitic dianhydride (166.56mg; 0.7636 mmol), Triethylamine (128.81 mg; 177.42 μΐ; 1.2728 mol), Stannous Octotate (7 mg; 5.6 μΐ; 0.1 w/w) and Toluene (40 ml). The reaction mixture was heated to a temperature of 115°C while stirring to allow the solvent to reflux. The reaction was carried out under these conditions for 24 h, after which reaction mixture was cooled and solvent was evaporated under reduced pressure. The residue dissolved in 10 ml methylene chloride and precipitated in 500 ml cold diethyl ether under vigorous stirring. The white polymer was collected by filtration under suction and dried under vacuum to a constant dry weight (6.2 g).
Example 3
[00037] This example describes the chain extension of the pre-polymer from example 1 with the incorporation of an aliphatic linker to impart multifunctionality.
[00038] A 250 ml three necked round-bottomed flask fitted with a reflux condenser, magnetic stirrer, heat-on-block and under a gentle purge of nitrogen, was charged with PLA-PEG400 (8 g; 0.7273 mmol), Cyclohexane tetracarboxylic dianhydride (195.66 mg; 0.8728 mmol), Triethylamine (147.25 mg; 202.82 μΐ; 1.455 mmol), Stannous Octoate (8 mg; 6.4 μΐ; 0.1% w/w) and Toluene (50 ml). The reaction mixture was heated to a temperature of 115°C while stirring to allow the solvent to reflux. The reaction was carried out under these conditions for 24 h, after which reaction mixture was cooled and solvent was evaporated under reduced pressure. The residue dissolved in 10 ml methylene chloride and precipitated in 400 ml cold diethyl ether under vigorous stirring. The white polymer was collected by filtration under suction and dried under vacuum to a constant dry weight (6.1 g).
Example 4 [00039] This examples describes the synthetic process of the aminated version of hP2-400 (hP2-400-EDA) described in example 3 using EDA.
[00040] A 50 ml three necked round bottomed flask equipped with magnetic stirrer and under a gentle purge of nitrogen was charged with hP2-400 (250 mg; 0.0142mmol; 11 COOH/mol), EDC (40.83 mg; 0.2131 mmol) and DMF (3 ml) and stirred at room temperature for 30 min. n-boc-EDA (34.12 mg; 33.72 μΐ; 0.213 mmol) and DIEA (27.53 mg; 37.1 μΐ) were subsequently added to the sitting solution and the reaction was continued for 18 h. The polymer was obtained by precipitation after pouting the reaction mixture in cold water. The precipitate was washed twice with water and dried under vacuum. The dried polymer was dissolved in 2.2 ml of 10: 1 mixture of CH2C12:TFA and stirred at room temperature for 1 h under nitrogen atmosphere. The solvent was then stripped off on a rotary evaporator and product washed with water to get a white polymer. The hP2-400-EDA polymer was dried under vacuum to a constant dry weight (195 mg).
Example 5
[00041] This examples describes synthesis process of the thioester version of pP2-400 described in example 2 using 2-mercaptoethanol.
[00042] A 50 ml three necked round bottomed flask equipped with magnetic stirrer, condensor and a heat-on block, and under a gentle purge of nitrogen was charged with pP2-400 (100 mg; O.Ol lmmol; 13 COOH/mol), 2-mercaptoethanol (12.89 mg;11.61 μΐ; 0.165 mmol), methanesulfonic acid (15.86mg; 10.71 μΐ; 0.165 mmol) and DMF (2ml). The reaction mixture was stirred at 100°C for 24 h, after which the product was obtained by precipitation in cold water. The product was further washed four times with water until the sulfur smell was eliminated and dried under vacuum to a constant dry weight (57.7 mg).
Example 6
[00043] This examples describes the conjugation of Gambogic acid to the aminated hP2-400 described in example 4.
[00044] A 50 ml three necked round bottomed flask equipped with magnetic stirrer and under a gentle purge of nitrogen was charged with gambogic acid (65.2 mg; 0.1037 mmol), EDC (29.83 mg; 0.1556 mmol) and CH2C12 (1 ml) and stirred at ambient temperature for 30 min. hP2-400-EDA (125 mg; 0.0069 mmol) pre-dissolved in CH2C12 (2 ml) and DIEA (20.11 mg; 27.1 μΐ; 0.1556 mmol) were subsequently added to the stirring solution and the reaction was carried out at these conditions for another 18 h. The product was obtained by precipitation in cold ether. The polymer was further washed one with ether and another time with water and dried under vacuum to a constant dry weight (104 mg). Example 7
[00045] This example describes the conjugation of Galactose to hP2-400 described in example 3.
[00046] A 50 ml three necked round bottomed flask equipped with magnetic stirrer and a heat-on block, and under a gentle purge of nitrogen was charged with hP2-400 (250 mg; 0.0142mmol; 11 COOH/mol), D-galactose (38.39 mg; 0. 2131 mmol), methanesulfonic acid (20.48 mg; 13.83 μΐ; 0.2131 mmol) and DMF (3ml). The reaction mixture was stirred at 60°C for 24 h, after which the product was obtained by precipitation in cold water. The product was further washed twice with water and dried under vacuum to a constant dry weight (242.1 mg).
Example 8
[00047] This example describes the conjugation of arginylglycylaspartic acid (RGD peptide) to hP2-400 described in example 3.
[00048] A 50 ml three necked round bottomed flask equipped with magnetic stirrer and under a gentle purge of nitrogen was charged with hP2-400 (150 mg; 0.0085mmol; 11 COOH/mol), EDC (24.44 mg; 0.1275 mmol) and DMF (2 ml) and stirred at room temperature for 30 min. RGD (44.16 mg; 0.1275 mmol) pre-dissolved in 1 ml DMF and DIEA (16.48 mg; 22.21 μΐ; 0.1275 mmol) were subsequently added to the stirring solution and the reaction was continued at these conditions for 18 h. The product was obtained by precipitation in cold water. The polymer was further washed twice in water and dried under vacuum to a constant dry weight (122 mg).
Example 9
[00049] This example describes the conjugation of fluorescent probe, Fluorescein to aminated hP2-400 described in example 4. [00050] A 50 ml three necked round bottomed flask equipped with magnetic stirrer and under a gentle purge of nitrogen was charged with hP2-400-EDA (25 mg; 0.00128 mmol; 9 NH2/mol), NHS-Fluorescein (7.24 mg; 0.0153 mmol), DIEA (1.98 mg; 2.7 μΐ; 0.0153 mmol) and DMF (1 ml). The reaction mixture was stirred in dark under inert atmosphere for 18 h. The product was obtained by precipitation in cold water. The polymer was further washed twice in water and dried under vacuum to a constant dry weight (12.5 mg).
Example 10
[00051] This example describes the conjugation of Hesperetin to pP2-400 described in example 2.
[00052] A 50 ml three necked round bottomed flask equipped with magnetic stirrer and under a gentle purge of nitrogen was charged with pP2-400 (100 mg; 0.0105 mmol; 11 COOH/mol), EDC (30.19 mg; 0.1575 mmol) and DMF (1 ml) and stirred at room temperature for 30 min. Hesperetin (47.61 mg; 0.1575 mmol) and DMAP (1.92 mg; 0.01575 mmol) pre-dissolved in 1 ml DMF were subsequently added to the stirring solution and the reaction was continued at these conditions for 18 h. The product was obtained by precipitation in cold water. The polymer was further washed twice and dried under vacuum to a constant dry weight.
Example 11 [00053] This example describes the conjugation of 1-Lysine to pP2-400 described in example 2.
[00054] A 50 ml three necked round bottom flask equipped with a magnetic stirrer and under a gentle purge of nitrogen was charged with pP2-400 (100 mg; 0.1 mmol; 11 COOH/mol), EDC (28.75 mg; 0.15 mmol) and DMF (0.5 ml) and stirred at ambient temperature for 30 min. 1-Lysine (21.93 mg; 0.15 mmol) predissolved in DMF (0.5 ml) and DIEA (19.39mg; 26.13 μΐ; 0.15 mmol) were subsequently added to the reaction flask and the reaction was carried out under nitrogen atmosphere and room temperature for 18 h. A pale yellow product was obtained by precipitation in water. The polymer was further washed twice with water and dried under vacuum to a constant dry weight (82.9 mg). Example 12
[00055] This example describes the conjugation of Cysteine to pP2-400 described in example 2. [00056] A 50 ml three necked round bottom flask equipped with a magnetic stirrer and under a gentle purge of nitrogen was charged with pP2-400 (100 mg; 0.1 mmol; 11 COOH/mol), EDC (28.75 mg; 0.15 mmol) and DMF (0.5 ml) and stirred at ambient temperature for 30 min. Cysteine (18.17 mg; 0.15 mmol) predissolved in DMF (0.5 ml) and DIEA (19.39 mg; 26.13 μΐ; 0.15 mmol) were subsequently added to the reaction flask and the reaction was carried out under nitrogen atmosphere and room temperature for 18 h. A pale yellow polymer was obtained by precipitation in water. The polymer was further washed twice with water and dried under vacuum to a constant dry weight (65.1 mg).
Example 13 [00057] This example describes the conjugation of Arginine to pP2-400 described in example 2.
[00058] A 50 ml three necked round bottom flask equipped with a magnetic stirrer and under a gentle purge of nitrogen was charged with pP2-400 (100 mg; 0.1 mmol; 11 COOH/mol), EDC (28.75 mg; 0.15 mmol) and DMF (0.5 ml) and stirred at ambient temperature for 30 min. 1-Arginine (26.13 mg; 0.15 mmol) predissolved in DMF (0.5 ml) and DIEA (19.39 mg; 26.13 μΐ; 0.15 mmol) were subsequently added to the reaction flask and the reaction was carried out under nitrogen atmosphere and room temperature for 18 h. A pale yellow polymer was obtained by precipitation in water. The polymer was further washed twice with water and dried under vacuum to a constant dry weight (87.6 mg). Example 14
[00059] This example describes the conjugation of Paclitaxel to pP2-400 described in example 2.
[00060] A 50 ml three necked round bottomed flask equipped with magnetic stirrer and under a gentle purge of nitrogen was charged with pP2-400 (100 mg; 0.0072mmol; 10 COOH/mol), EDC (20.70 mg; 0.108 mmol) and DMF (0.5 ml) and stirred at room temperature for 30 min. Paclitaxel (92.2 mg; 0.108 mmol) and DMAP (1.32 mg; 0.0108 mmol) pre-dissolved in 0.5 ml DMF were subsequently added to the stirring solution and the reaction was continued at these conditions for 18 h. The product was obtained by precipitation in cold 1 : 1 mixture of ethanol and ethyl ether. The polymer was further washed twice and dried under vacuum to a constant dry weight (75 mg). Example 15
[00061] This example describes the conjugation of Paclitaxel to hP2-400 described in example 3.
[00062] A 50 ml three necked round bottomed flask equipped with magnetic stirrer and under a gentle purge of nitrogen was charged with hP2-400 (100 mg; 0.00521 mmol; 9 COOH/mol), EDC (11.98 mg; 0.0625 mmol) and DMF (0.5 ml) and stirred at room temperature for 30 min. Paclitaxel (53.37 mg; 0.0625 mmol) and DMAP (0.76 mg; 0.00625 mmol) pre-dissolved in 0.5 ml DMF were subsequently added to the stirring solution and the reaction was continued at these conditions for 18 h. The product was obtained by precipitation in cold 1 : 1 mixture of ethanol and ethyl ether. The polymer was further washed twice and dried under vacuum to a constant dry weight (75 mg).
Example 16
[00063] This example describes the conjugation of Cisplatin to hP2-400 described in example 2. [00064] A 50 ml three necked round bottom flask equipped with a magnetic stirrer and under a gentle purge of nitrogen was charged with pP2-400 (100 mg; 0.1 mmol; 8 COOH/mol), EDC (19.71 mg; 0.1 mmol) and DMF (1 ml) and stirred at ambient temperature for 30 min. Cisplatin (30 mg; 0.1 mmol) predissolved in DMF (1 ml) and DIEA (12.92 mg; 17.42 μΐ; 0.1 mmol) were subsequently added to the reaction flask and the reaction was carried out in the dark under nitrogen atmosphere and room temperature for 24 h. A yellow conjugated polymer was obtained by precipitation in water. The polymer was further washed twice with water and dried under vacuum to a constant dry weight (84.3 mg).
Example 17
[00065] This example describes the conjugation of Gemcitabine to pP2-400 described in example 2.
[00066] A 50 ml three necked round bottom flask equipped with a magnetic stirrer and under a gentle purge of nitrogen was charged with pP2-400 (100 mg; 0.1 mmol; 8 COOH/mol), EDC (19.71 mg; 0.1 mmol) and DMF (1 ml) and stirred at ambient temperature for 30 min. Gemcitabine (26.32 mg; 0.1 mmol) predissolved in DMF (1 ml) and DIEA (12.92 mg; 17.42 μΐ; 0.1 mmol) were subsequently added to the reaction flask and the reaction was carried out in the dark under nitrogen atmosphere and room temperature for 24 h. A yellow conjugated polymer was obtained by precipitation in water. The polymer further washed twice with water and dried under vacuum to a constant dry weight (80.6 mg). Example 18
[00067] This example describes the conjugation of Withaferin A to pP2-2000H (A variation of pP2-400 described in example 2 with 2000 g/mol PEG chains and higher lactide concentration per chain of final polymer).
[00068] A 50 ml three necked round bottomed flask equipped with magnetic stirrer and under a gentle purge of nitrogen was charged with pP2-2000H (50 mg; 0.0017 mmol; 7 COOH/mol), EDC (3.26 mg; 0.017 mmol) and DMF (1 ml) and stirred at room temperature for 30 min. Withaferin A (8.0 mg; 0.017 mmol) and DMAP (0.21 mg; 0.0017 mmol) pre-dissolved in 1 ml DMF were subsequently added to the stirring solution and the reaction was continued at these conditions for 18 h. The product was obtained by precipitation in cold water. The polymer was further washed twice and dried under vacuum to a constant dry weight.
Example 19
[00069] This example describes the conjugation of diagnostic agents to P2s.
[00070] P2s can be functionalized with diagnostic agents e.g. MRI and ultrasound contrast agents, Near-IR fluorescent agents etc. by coupling them to the carboxyl or amine functionality of the P2s via ester or amide bonds based on the available functional unit of the agent. Both the processes involve activation of carboxyl on either the polymer or the diagnostic moiety by EDC followed by either amination in the presence of DIEA or esterification in the presence of DMAP. Alternatively, Fischer esterification can be employed to conjugate a moiety with hydroxyl functionality to the carboxylated P2, if the said moiety can withstand higher temperatures and strong acid catalyst.
Example 20
[00071] This example describes the use of P2s for coupling moieties of different functionalities. [00072] The methods described in examples 4-19 can be employed on any and all P2s listed in table 3. All P2s can be aminated or thiolated and coupled to ligands, labeling and diagnostic agents, drug molecules etc. as described for the model P2s in the above mentioned examples. The choice of polymer is subject to the requirements for the end product in terms of level of multifunctionality, molecular weight and degradation profile. Fig. 1A shows the decrease in molecular weight of hP2-400 and Fig. IB shows the degradation profile of hP2-400 over a period of 96 hours. Fig. 1C shows the decrease in molecular weight of hP2-1000H and Fig. ID shows the degradation profile of hP2-1000H over a period of 96 hours. Fig. IE shows the decrease in molecular weight of hP2-2000H and Fig. IF shows the degradation profile of hP2-2000H over a period of 96 hours.
Example 21
[00073] This example describes the general preparation of NS of P2s.
[00074] Due to the multifunctional nature of P2s, large amount of ligand molecules can be attached to the polymer chains resulting in an increase in weight without the increase in chain length. To compensate for the lower level of backbone polymer available in conjugated polymers, additional plain P2s are added equal to the amount of ligand available on the polymer. To prepare NS, 25 mg of P2s or conjugated P2s (with additional plain P2s equal to cumulative ligand weight) were solubilized in 1.25 ml (2% w/v) mixture of CH2C12 and Ethyl acetate (based on their solubility; table 1) and emulsified in a 2.5 ml (0.1-2 %w/v) solution of a stabilizer like DMAB, PVA, TPGS or a combination of the stabilizers. The emulsion was stirred at 1500 rpm for 5 min followed by homogenization at 15000 rpm for 7 min. The final emulation was diluted with 10 ml water and stirred at 1000 rpm for 3 h. The NS were collected by centrifugation at 15000-20000xg at 4°C for 30 minutes. The pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried. The emulsification process can be modified based on the physico-chemistry of different drugs to be encapsulated to maximize entrapment efficiency.
Example 22
[00075] This example described the preparation of fluorescent P2Ns from hP2- 400, hP2-400-GA, hP2-400-Gal and hP2-400-RGD described in examples 3, 6, 7 and 8 with incorporation of hP2-400-fluoroscein described in example 9. [00076] Due to the multifunctional nature of hP2-400, large amount of ligand molecules can be attached to the polymer chains resulting in an increase in weight without the increase in chain length. To compensate for the lower level of backbone polymer available in conjugated hP2-400, additional plain hP2-400 was added equal to the amount of ligand available on the polymer. To prepare NS, 25 mg of hP2-400 or conjugated hP2-400 (with additional plain polymer equal to cumulative ligand weight) were mixed with 1 mg hP2-400-fluorescein and the mixture was solubilized in 1.25 ml (2% w/v) in a 1 :4 mixture of CH2C12 and ethyl acetate. The organic phase was emulsified in a 2.5 ml (1% or 0.5 %w/v) solution of DMAB. The emulsion was stirred at 1500 rpm for 5 min followed by homogenization at 15000 rpm for 7 min. The final emulation was diluted with 10 ml water and stirred at 100 rpm for 3 h. The NS were collected by centrifugation at 15000-20000xg at 4°C for 30 minutes. The pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried.
Example 23 [00077] This example describes the encapsulation of Paclitaxel in NS of P2s.
[00078] To prepare paclitaxel loaded NS, 50 mg P2s and paclitaxel (5, 10, 15 or 20% w/w based on loading amount) were solubilized in 5 ml mixture of CH2C12 and ethyl acetate (based on their solubility; tablel) and emulsified in a 5 ml (1% w/v) solution of DMAB. The emulsion was stirred at 1500 rpm for 5 min followed by homogenization at 15000 rpm for 5 min. The final emulation was diluted with 20 ml water and stirred at 1000 rpm for 3 h. The NS were collected by centrifugation at 15000xg at 4°C for 30 minutes. The pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried.
Example 24 [00079] This example describes the encapsulation of Insulin in NS of P2s.
[00080] Insulin loaded P2s-NS were prepared using a double emulsion technique. 50 mg P2s were dissolved in 3 ml mixture of CH2C12 and ethyl acetate (based on their solubility; tablel). Insulin was separately dissolved in 0.5 ml 1.5% (w/v) solution of PVA in 0.01M HC1 in an amount equal to 5, 10 or 15% (w/w) of the polymer content based on intended loading. The aqueous phase containing insulin was emulsified in the organic phase containing polymer and stirred at 1500 rpm for 3 min. this primary emulsion was then added to 10.5 ml 1.5% (w.v) PVA solution in water to form a secondary emulsion which was further stirred for 3 min at 1500 rpm. The emulsion was homogenized at 15000 rpm for 7 min followed by dilution in 20 ml water. The final suspension was stirred for 3 h at 1000 rpm to allow the organic solvent to diffuse out and evaporate. The NS were collected by centrifugation at 15000xg at 4°C for 30 minutes. The pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried.
Example 25
[00081] This example describes the encapsulation of Cyclosporine A in P2s_NS.
[00082] To prepare cyclosporine A loaded NS, 50 mg P2s and cyclosporine A (5, 10 or 15% w/w based on loading amount) were solubilized in 2.5 ml mixture of CH2C12 and Ethyl acetate (based on their solubility; tablel) and emulsified in a 5 ml (0.1% w/v) solution of DMAB. The emulsion was stirred at 1500 rpm for 1 min followed by probe sonication at 20% amplitude for 30 s. The final emulation was diluted with 20 ml water and stirred at 1000 rpm for 3 h. The NS were collected by centrifugation at 15000xg at 4°C for 30 minutes. The pellets of NS were suspended in 0.5 ml 5% (w/v) solution of trehalose dehydrate in water and freeze dried.
Example 26 [00083] This example describes the uptake of fluorescent P2Ns of hP2-400 described in example 22 in Caco-2 cells monolayers.
[00084] Freeze-dried fluorescent P2NS and PLGA NS (plain or conjugated to GA, Gal or RGD) were suspended in dH20 at a concentration of 50 and 250 μg/ml respectively. Caco-2 cells were incubated with the 200 μΐ of F-NS suspension for 5 min at 37 °C/5% C02, followed by addition serum free medium and further incubation for lh at 37 °C/5% C02. The cells were washed three times with phosphate buffered saline (PBS, pH 7.4) and further processed for fluorescent microscopy and FACS for uptake. Example 27
[00085] This example describes the evaluation of non -competitive binding of fluorescent P2Ns-GA of hP2-400 described in example 22 to transferrin receptor (TfR) in Caco-2 cells monolayers. [00086] The TfR on Caco-2 mololayers were blocked using human specific
TfR primary antibody by incubating for 30 min at 37°C in CO2 incubator. After three consecutive washings with PBS, P2Ns-GA were added and incubated for further 1 h. These were then washed with PBS 3 times and trypsinized and subjected to FACS analysis.
Example 28 [00087] This example describes the uptake of fluorescent P2Ns of hP2-400 described in example 22 in ex vivo intestinal tissue.
[00088] To study the uptake of P2Ns in intestinal tissue, 4 μιη cryosections of previously excised small intestine were treated with fluorescent plain or ligand conjugated P2Ns suspension in PBS. After lh incubation at 37°C, the sections were washed multiple times to remove unbound un-internalized NS followed by staining of actin and mounting with mountant containing DAPI.
Example 29
[00089] This example describes the evaluation of non -competitive binding of fluorescent P2Ns-GA of hP2-400 described in example 22 to transferrin receptor (TfR) in ex vivo small intestine tissue sections.
[00090] The TfR on 4 μιη cryosections of previously excised small intestine were blocked using human/mouse specific TfR primary antibody by incubating for 30 min at 37°C in CO2 incubator. After three consecutive washings with PBS, P2Ns-GA were added and incubated for further 1 h. These were then washed with PBS 3 times and processed for microscopic evaluation.
Example 30
[00091] This example describes the kinetics of fluorescent P2Ns of hP2-400 described in example 22 in vivo in Sprague Dawley rats. [00092] Male Sprague Dawley rats (300-320 g) were dosed perorally with fluorescent plain and conjugated P2Ns (16 mg/rat). Blood was collected via heart puncture at terminal sacrifice at 2, 12 and 24 h. Plasma and RBCs were processed for fluorescence quantification. The plasma kinetics shows ligand specific variable absorption, where those with no ligands were absorbed over extended periods of times suggesting they are lodged in the intestine. Fig. 2A shows the mean fluorescent intensity of fluorescent P2Ns of hP2-400 in RBCs. Fig. 2B shows the mean fluorescent intensity of fluorescent P2Ns of hP2-400 in plasma.
Table 1
[00093] Solubility of hP2s in mixture of methylene chloride and ethyl acetate
Figure imgf000021_0001
Table 2
[00094] Molecular weighs and composition of different PLA-PEG prepolymers with varying chain lengths of PEG and ratios of lactide or lactic acid to ethylene glycol and the constituent PEG molecules
Figure imgf000021_0002
Table 3
[00095] Range of P2s prepared by chain extending prepolymers from table 1 with their respective molecular weight profiles and mol/mol carboxyl side groups perdiosically placed along the polymer chains.
*PMDA: Pyromellitic dianhydride; HCDA: Cyclohexanetetracarboxylic dianhydride
Figure imgf000022_0001
Table 4
[00096] Particle size and entrapment efficiency of Paclitaxel in P2s-NS and conventional PLGA (for comparison)
Figure imgf000022_0002
Table 5
[00097] Particle size and entrapment efficiency of Insulin in P2s-NS and conventional PLGA (for comparison)
Figure imgf000023_0001
Table 6
[00098] Particle size and entrapment efficiency of Cyclosporine A in hP2-
2000H
Figure imgf000023_0002
[00099] While the invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims

CLAIMS What is claimed is:
1. A composition comprising: one or more biodegradable block copolymer drug carriers comprising A-B, A-B-A or B-A-B block copolymers, wherein the A block is a biodegradable polyester and the B block is polyethylene glycol (PEG); and a plurality of pendent carboxyl groups derived from aromatic or aliphatic dianhydrides incorporated within the block copolymer backbone.
2. The composition according to claim 1, wherein the free pendent carboxyl groups are covalently bonded to a ligand with amine, carboxyl or hydroxyl functionality.
3. The composition according to claim 1, further comprising a diamine linker that is conjugated to the carboxyl groups of the block copolymer backbone.
4. The composition according to claim 1, wherein the free amine moiety of the diamine linker is covalently connected to a ligand.
5. The composition according to claim 1 further comprising a drug physically encapsulated or coupled to contrast or near IR agents.
6. The composition according to claim 1 further comprising a single or multiple drugs chemically conjugated to the polymer system forming polymer-drug conjugates.
7. The composition according to claim 5-6, wherein the drug has limited aqueous solubility or permeability or both.
8. The composition according to claims 1-7, wherein the composition forms polymer nanosystems or drug conjugates for therapy or diagnosis.
9. An aqueous composition comprising the composition of claim 1 reconstituted in an aqueous vehicle, wherein said composition is a uniform colloidal system.
10. The composition according to claim 8, wherein the composition comprises covalently bound ligands on the surface that interact non-competitively with receptors on the cell membranes for receptor-mediated uptake.
11. The composition according to claim 10, wherein the composition comprises two or more ligands to tailor the distribution profile of the composition in the subject.
12. A method of administration comprising reconstituting the composition of claim 1 by addition of water or an aqueous solution to form a uniform colloidal system; and administering the uniform colloidal system to a subject.
13. The method of administration of claim 10, wherein the administering step is through the oral or peroral route.
14. The method of administration of claim 10, wherein the administering step is by nose, skin or injection.
PCT/US2016/028104 2015-04-18 2016-04-18 Polymer systems and their applications in diagnostics and drug delivery Ceased WO2016172042A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/567,370 US10780175B2 (en) 2015-04-18 2016-04-18 Polymer systems and their applications in diagnostics and drug delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562149563P 2015-04-18 2015-04-18
US62/149,563 2015-04-18

Publications (1)

Publication Number Publication Date
WO2016172042A1 true WO2016172042A1 (en) 2016-10-27

Family

ID=57143396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/028104 Ceased WO2016172042A1 (en) 2015-04-18 2016-04-18 Polymer systems and their applications in diagnostics and drug delivery

Country Status (2)

Country Link
US (1) US10780175B2 (en)
WO (1) WO2016172042A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3655017B1 (en) 2017-07-17 2025-01-22 Medincell S.A. Pharmaceutical composition
JP6875361B2 (en) * 2018-12-25 2021-05-26 ファナック株式会社 Control method of wire electric discharge machine and wire electric discharge machine
US11504339B2 (en) 2020-01-30 2022-11-22 The Texas A&M University System Compositions comprising urolithin a and uses thereof in treating kidney injury
CN114835888B (en) * 2022-04-18 2023-08-08 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） A nano-carrier system, drug-loading system and application of tumor in situ assembly

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068377A1 (en) * 2001-10-03 2003-04-10 Macromed, Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US20100260743A1 (en) * 2006-01-19 2010-10-14 Allexcel, Inc. Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101236198B1 (en) * 2011-02-08 2013-02-22 아주대학교산학협력단 Polyethyleneglycol/polyester block copolymers with side functional group as biocompatible thermo-sensitive materials and manufacturing method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068377A1 (en) * 2001-10-03 2003-04-10 Macromed, Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US20100260743A1 (en) * 2006-01-19 2010-10-14 Allexcel, Inc. Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers

Also Published As

Publication number Publication date
US20180110865A1 (en) 2018-04-26
US10780175B2 (en) 2020-09-22

Similar Documents

Publication Publication Date Title
Li et al. Towards the development of polycaprolactone based amphiphilic block copolymers: molecular design, self-assembly and biomedical applications
Prabaharan et al. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery
CA2672551C (en) Biodegradable block copolymeric compositions for drug delivery
CN101961494B (en) Star polymer nano-medicament carrier preparation used for intracellular medicament delivery and preparation method thereof
CN103298838B (en) pH-sensitive hyaluronic acid derivatives and applications thereof
CN101787119A (en) Polymer with tumor organization pH responsiveness and micelle thereof
KR20010010393A (en) Biodegradable Block Copolymer of Hydrophobic and Hydrophilic Polymers, and Composition for Drug Delivery Comprising Same
JP5933889B2 (en) Novel poly (ethylene oxide) -block-poly (ester) block copolymer
US20160058698A1 (en) Composition for controlled delivery of bioactive agents
ES2287297T3 (en) POSITIVELY LOADED AMPHIFILOUS BLOCK COPOLYMER AS A VEHICLE FOR PHARMACO AND COMPLEX SAME WITH NEGATIVELY CHARGED PHARMACO.
US10780175B2 (en) Polymer systems and their applications in diagnostics and drug delivery
Papaneophytou et al. Polyhydroxyalkanoates applications in drug carriers
JP2008530206A (en) Polymer particle delivery compositions and methods of use
CN101331173A (en) Biocompatible block copolymers, their uses and methods of manufacture
Luo et al. The targeting properties of folate-conjugated Pluronic F127/poly (lactic-co-glycolic) nanoparticles
CN105860057B (en) Biodegradable polymer based on the hydrophilic polyaminoacid of hydrophobic function small molecule and its preparation method and application
US20110070320A1 (en) Biodegradable thermoresponsive 3-arm polyethylene glycol poly(lactide-co-glycolide) copolymer for ginseng administration
CN103251955A (en) High-molecular targeted drug carrier used for bladder tumor perfusion treatment, and preparation method thereof
CN100427144C (en) A kind of degradable thermosensitive physical hydrogel and preparation method thereof
CN101156952B (en) DC cell targeting carrier, nanoparticle and preparation method
Efthimiadou et al. New approach in synthesis, characterization and release study of pH-sensitive polymeric micelles, based on PLA-Lys-b-PEGm, conjugated with doxorubicin
US20160082109A1 (en) Copolymer and nanoparticles obtained therefrom for drug delivery
CN1965802B (en) A kind of injectable hydrogel preparation of pegylated drug and preparation method thereof
KR102922427B1 (en) Self-assembled nanoparticles comprising polymer of glycocholic acid-polymer conjugate, preparation method thereof and drug delivery composition containing the same
Sharma et al. Diblock and triblock copolymers of polylactide and polyglycolide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16783652

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15567370

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16783652

Country of ref document: EP

Kind code of ref document: A1